TABLE 3.
Immune response of healthy adults to the protein carrier in GBS III-TT conjugate vaccine in the absence or presence of aluminum hydroxide
| Vaccine CPS dose (μg) | Adsorbed alum (μg)a | No. of recipients | GMC (μg/ml) of TT-specific IgG (95% CI; range)b at wk after vaccination:
|
|
|---|---|---|---|---|
| 0 | 4 | |||
| 50 | 0 | 15 | 84.3c (59.3–119.7; 15.0–277) | 950d (526–1,714; 285–12,462) |
| 12.5 | 125 | 15 | 66.9e(40.4–110.9; 13.3–287) | 181f (113–292; 32.3–1,450) |
| 12.5 | 0 | 15 | 51.2 (33.2–78.9; 5.9–149) | 295 (207.0–419.7; 118–1,277) |
| 3.125 | 125 | 15 | 97.4 (66.1–143.5; 26.2–310) | 151 (112.7–203.7; 72.5–392) |
a
Aluminum hydroxide.
b
95% CI, 95% confidence interval.
c
P > 0.05 compared with the 12.5-μg dose with alum at week 0.
d
P = 0.001 compared to all other groups at week 4.
e
P = 0.39 compared with the 12.5-μg dose without alum.
f
P = 0.089 compared with the 12.5-μg dose without alum; P = 0.49 compared with the 3.125-μg dose with alum.